Verona Pharma's core business segment revolves around the research, development, and clinical advancement of novel therapies for respiratory diseases. This includes the ongoing Phase III clinical trials for ensifentrine, a dual inhibitor of PDE3 and PDE4, targeting conditions like COPD, cystic fibrosis, and asthma. The company employs various formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler, to optimize drug delivery and patient outcomes. R&D efforts focus on refining ensifentrine's efficacy and safety profile, exploring new indications, and developing next-generation respiratory treatments. The ultimate goal is to provide innovative solutions that improve the quality of life for patients suffering from chronic respiratory ailments, addressing unmet medical needs in this therapeutic area.